- Biopharmaceutical solutions organization, Syneos Health (SYNH +5.4%) has been upgraded to Buy from Neutral at Goldman Sachs with a price target of $75 (33% upside), up from $69.
- According to analyst, Syneos's shares have underperformed (dipped 14%) over the past month, which does not reflect the improving outlook for the company and momentum in both of its segments. He views current levels as an attractive entry point for shares.
- https://seekingalpha.com/news/3619052-syneos-health-ticks-higher-on-buy-rating-from-goldman-sachs
Thursday, October 1, 2020
Syneos Health ticks higher on 'Buy' rating from Goldman
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.